A comparative study on proteomics between LNCap and DU145 cells by quantitative detection and SELDI analysis
- 135 Downloads
- 2 Citations
Summary
The differences in intracellular and extracellular protein expressions between human prostate cancer lines LNCap and DU145 were examined. The proteins of the two cell lines were extracted and condensed by using protein extraction kits. And the intracellular and extracellular proteins were quantitatively detected on a micro-plate reader by using bicinchoninic acid (BCA) method. The proteins in cell culture fluid were qualitatively assayed by SELDI-TOF-MS. The results showed that the intracellular protein contents of LNCap cells were extremely higher than those of DU145 cells. After serum-free culture, both intracellular and extracellular protein contents of LNCap and DU145 were decreased to some extent. And the intracellular proteins were decreased by 5% in LNCap and by 36% in DU145 respectively, while the extracellular proteins were decreased by 89% in LNCap and 96% in DU145 respectively. SELDI assay revealed that there were 5 marker proteins in LNCap and 6 in DU145. Although both LNCap and DU145 cell lines originated from human prostate cancer, they had some differences in protein expression.
Key words
prostate cancer LNCap DU145 protein quantitative and qualitative study SELDI-TOF-MSPreview
Unable to display preview. Download preview PDF.
References
- 1.Kambhampati S, Ray G, Sengupta K et al. Growth factors involved in prostate carcinogenesis. Front Biosci, 2005,1(10):1355–1367CrossRefGoogle Scholar
- 2.Engwegen J Y, Gast M C, Schellens J H et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci, 2006,27(5):251–259PubMedCrossRefGoogle Scholar
- 3.Roboz J. Mass spectrometry in diagnostic oncoproteomics. Cancer Invest, 2005,23(5):465–478PubMedGoogle Scholar
- 4.Pan Y Z, Xiao X Y, Zhao D et al. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. Asian J Androl, 2006,8(1):45–51PubMedCrossRefGoogle Scholar
- 5.Hellström M, Lexander H, Franzén B et al. Proteomics in prostate cancer research. Anal Quant Cytol Histol, 2007, 29(1):32–40PubMedGoogle Scholar
- 6.Skytt A, Thysell E, Stattin P et al. SELDI-TOF-MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer, 2007,121(3):615–620PubMedCrossRefGoogle Scholar
- 7.Semmes O J, Feng Z, Adam B L et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reprocibility. Clin Chem, 2005,51(1):102–112PubMedCrossRefGoogle Scholar
- 8.Kohli M, Siegel E, Bhattacharya S et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for deter mining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark, 2006,2(6):249–258PubMedGoogle Scholar
- 9.Faria P C, Saba K, Neves A F et al. Transforming growth factor-beta 1 gene poly-morphisms and expression in the blood of prostate cancer patients. Cancer Invest, 2007,25(8):726–732PubMedCrossRefGoogle Scholar
- 10.Ghosh R, Garcia G E, Crosby K et al. Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia, 2007,9(11):893–899PubMedCrossRefGoogle Scholar
- 11.Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem, 2005,51(4):695–707PubMedCrossRefGoogle Scholar
- 12.Malik G, Ward M D, Gupta S K et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res, 2005, 11(3):1073–1085PubMedGoogle Scholar
- 13.Engwegen J Y, Helgason H H, Cats A et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol, 2006, 12(10): 1536–1544PubMedGoogle Scholar
- 14.Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem, 2005, 51(4):695–707PubMedCrossRefGoogle Scholar
- 15.Park Y, Downing S R, Kim D et al. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics, 2007, 23(12):1451–1458PubMedCrossRefGoogle Scholar